Anal Cancer Clinical Trial
Official title:
Assessing Drivers and Barriers to Follow-Up Screening for Anal Cancer in Men Who Have Sex With Men
This study is designed to identify barriers that prevent men who have sex with men from
receiving doctor-recommended annual follow-up screenings for anal cancer. Men who are at the
highest risk for developing anal cancer will be asked to complete a brief questionnaire
(either via telephone or in writing). The questionnaire is designed to identify potential
barriers to care-seeking behavior including, relationship status, financial constraints,
highest level of education and knowledge about anal cancer and its precursors. The men who
agree to participate in the study will then be organized into groups based on their history
of coming in for follow-up screening visits after learning that they are at higher risk for
developing anal cancer. These groups include 1) men that have come in for regular screening
visits (at least once per year), 2) men who came in once and were then lost to follow-up, 3)
men who came in for more than one screening visit and were then lost to follow-up, and 4)
men who were previously lost to follow-up and then began coming in for screening again. By
comparing the men's responses across the different groups, we hope to uncover key barriers
and drivers to follow-up screenings for anal cancer.
The goal of this study is to evaluate the differences in questionnaire responses across
cohorts that may impact care-seeking behavior.
We hypothesize that:
- Patients who regularly comply with annual follow-up screening visits score higher on
questions assessing knowledge of HPV and anal cancer.
- Men in stable relationships are more likely to comply with annual screening visit
recommendations.
- Men who are educated by their primary care physicians about the importance of anal
cancer screenings have higher screening rates.
200 subjects will be selected out of a pool of MSM patients in Dr. Stephen Goldstone's
private medical practice, Laser Surgery Care, who have in the past and/or are currently
being screened for anal dysplasia.
Subjects who come into the office for a follow-up appointment for anal condyloma and/or anal
dysplasia treatment will be asked to participate in the study. If written consent is
provided, subjects will be asked to complete a written questionnaire.
Subjects will also be selected out of a pool of patients who have been lost to follow-up,
defined as having failed to come in for a follow-up visit > 12 months after their last
appointment for treatment or screening for anal condyloma and/or anal dysplasia. These
subjects will be contacted via telephone and asked to participate in a brief telephone
interview (approximately 14 minutes in duration). The interview is identical to the written
questionnaire. At the conclusion of the interview, subjects will be given the opportunity to
schedule a follow-up appointment.
Medical records for all subjects who agree to participate in the study will be used to
confirm screening visit history as well as history and severity of dysplasia. In addition,
HIV status will also be confirmed by review of the medical chart. Data will be entered into
an anonymous medical record summary sheet. Information will then be entered into an
electronic database identified only by subject number.
Subjects will be divided into cohorts based on follow-up care seeking behavior: 1) those who
come in for regular screening defined as at least once per year, 2) those who came in once
and were lost to follow-up, 3) those who came in for more than one screening visit and were
then lost to follow-up, and 4) those who were previously lost to follow-up and then began
coming in for screening again. Questionnaire responses will be compared across cohorts to
determine which variables differ significantly. t-Tests, one way, and multivariate analysis
of variance, and correlation analysis will be used as indicated by variable type.
Patients will not receive any compensation for their participation in the study.
;
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05060471 -
PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients
|
Phase 2 | |
Active, not recruiting |
NCT02135419 -
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
|
Phase 3 | |
Completed |
NCT05518201 -
Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old
|
Phase 1 | |
Withdrawn |
NCT02857608 -
A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus
|
Phase 2 | |
Active, not recruiting |
NCT02546973 -
Quality of Life in Patients With Anal Cancer
|
||
Terminated |
NCT00903396 -
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
|
Phase 2 | |
Terminated |
NCT00896467 -
Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy
|
N/A | |
Completed |
NCT00550589 -
Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus
|
Phase 2 | |
Completed |
NCT00324415 -
Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer
|
Phase 2 | |
Terminated |
NCT00568425 -
QOL & Functional Outcomes After Combined Modality Tx for Anal CA: Comparison of Conventional vs IMRT
|
||
Terminated |
NCT00267787 -
Molecular Genetic and Pathological Studies of Anal Tumors
|
||
Completed |
NCT00066430 -
Infrared Coagulation in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia
|
Phase 1 | |
Completed |
NCT04083053 -
High-Resolution Anoscopy Perceived Discomfort Study
|
N/A | |
Completed |
NCT03506529 -
Identification of Predictive Factors for Physiological Hypermetabolism of the Anal Canal in 18F-FDG PET / CT
|
||
Recruiting |
NCT05835947 -
Anal Cancer Risk In Women
|
||
Not yet recruiting |
NCT03947775 -
HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL
|
Phase 2 | |
Recruiting |
NCT04857528 -
Detecting HPV DNA in Anal and Cervical Cancers
|
||
Recruiting |
NCT04708470 -
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
|
Phase 1/Phase 2 | |
Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
Active, not recruiting |
NCT01937780 -
Anal Cancer Radiotherapy Study
|